Compare Biogen Inc (BIIB) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs HCA Health Inc — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while HCA Health Inc trades at $411 (market cap $89.08B). The key difference: HCA Health Inc is far larger — about 3× Biogen Inc's market cap, and HCA Health Inc pays a 0.76% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | HCA | |
|---|---|---|
Market Cap | $30.13B | $89.08B |
Sector | Health | Health |
52-Week High | $216.63 | $545.13 |
52-Week Low | $128.93 | $361.32 |
Enterprise Value | $37.20B | $139.62B |
Dividend Yield | — | 0.76% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
